Aquestive Therapeutics, Inc. Stock Issued During Period, Value, Employee Stock Purchase Plan
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Aquestive Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2026-06-30 was $82.00K, a 38.98% increase year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2025-06-30 was $59.00K, a 28.26% increase year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2024-06-30 was $46.00K, a 48.39% increase year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for the quarter ending 2023-06-30 was $31.00K, a 106.67% increase year-over-year.
- Aquestive Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2025 was $191.00K, a 75.23% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2024 was $109.00K, a 65.15% increase from fiscal 2023.
- Aquestive Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2023 was $66.00K, a 94.12% increase from fiscal 2022.
- Aquestive Therapeutics, Inc. stock issued during period, value, employee stock purchase plan for fiscal 2022 was $34.00K, a 78.48% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Employee Stock Purchase Plan 3 month | Stock Issued During Period, Value, Employee Stock Purchase Plan 12 month |
|---|---|---|
| 2026-06-30 | $82.00K 10-Q · filed 2026-08-11 | |
| 2025-12-31 | $191.00K 10-K · filed 2026-03-04 | |
| 2025-06-30 | $59.00K 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $109.00K 10-K · filed 2026-03-04 | |
| 2024-06-30 | $46.00K 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $66.00K 10-K · filed 2025-03-05 | |
| 2023-06-30 | $31.00K 10-Q · filed 2024-11-04 | |
| 2022-12-31 | $34.00K 10-K · filed 2024-03-05 | |
| 2022-06-30 | $15.00K 10-Q · filed 2023-11-06 | |
| 2021-12-31 | $158.00K 10-K · filed 2023-03-31 | |
| 2021-06-30 | $76.00K 10-Q · filed 2022-11-01 | |
| 2020-12-31 | $158.00K 10-K · filed 2022-03-08 | |
| 2020-06-30 | $73.00K 10-Q · filed 2021-11-02 | |
| 2019-12-31 | $237.00K 10-K · filed 2021-03-09 | |
| 2019-06-30 | $132.00K 10-Q · filed 2020-11-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |